eMC - trusted, up to date and comprehensive information about medicines
Link to eMC medicine guides website
eMC homepage
Get Medicines Compendium UK app here

Bausch & Lomb U.K Limited

Bausch & Lomb House, 106 London Road, Kingston-upon-Thames, Surrey, KT2 6TN, UK
Telephone: +44 (0)208 781 2900
Fax: +44 (0)208 781 2901
Medical Information Direct Line: +44(0)1748 828849 or 08 1871 9318
Medical Information e-mail: medicalinformationuk@bausch.com
Customer Care direct line: +44 (0)208781 2991

Before you contact this company: often several companies will market medicines with the same active ingredient. Please check that this is the correct company before contacting them. Why?


Summary of Product Characteristics last updated on the eMC: 18/09/2007
SPC Minims Lidocaine & Fluorescein


Go to top of the page
1. NAME OF THE MEDICINAL PRODUCT

Minims Lidocaine & Fluorescein.


Go to top of the page
2. QUALITATIVE AND QUANTITATIVE COMPOSITION

Clear, slightly yellow, slightly viscous eye drops containing Lidocaine Hydrochloride PhEur 4% w/v and Fluorescein Sodium PhEur 0.25% w/v.


Go to top of the page
3. PHARMACEUTICAL FORM

Single-use, sterile eye drops.


Go to top of the page
4. CLINICAL PARTICULARS

Go to top of the page
4.1 Therapeutic indications

As a diagnostic stain and topical anaesthetic combined Minims Lidocaine & Fluorescein can be used in the measurement of intraocular pressure by Goldmann tonometry.


Go to top of the page
4.2 Posology and method of administration

Adults (including the elderly):

One or more drops, as required.

Children:

As directed by the physician.


Go to top of the page
4.3 Contraindications

Do not use in patients with a known hypersensitivity to fluorescein or lidocaine and other amide-type local anaesthetics.


Go to top of the page
4.4 Special warnings and precautions for use

The anaesthetised eye should be protected from foreign body contamination, particularly in elderly patients in whom the duration of anaesthesia may exceed 30 minutes.

Use with caution in an inflamed eye as hyperaemia greatly increases the rate of systemic absorption through the conjunctiva.

Systemic absorption may be reduced by compressing the lacrimal sac at the medial canthus for a minute during and following the instillation of the drops. (This blocks the passage of the drops via the naso-lacrimal duct to the wide absorptive area of the nasal and pharyngeal mucosa. It is especially advisable in children.)


Go to top of the page
4.5 Interaction with other medicinal products and other forms of interaction

None known.


Go to top of the page
4.6 Pregnancy and lactation

This combination has been used for a number of years without apparent ill-consequence.


Go to top of the page
4.7 Effects on ability to drive and use machines

None known.


Go to top of the page
4.8 Undesirable effects

ADRs are very rare( <1/10,000),including isolated reports.

Symptoms of allergic-type reactions and anaphylaxis have been reported following topical ophthalmic administration of Fluorescein sodium and may manifest as:

Eye disorders: allergic conjunctivitis, peri-orbital oedema

Immune system disorders: anaphylactic reaction

Skin and subcutaneous tissue disorders: urticaria, rash


Go to top of the page
4.9 Overdose

Overdose is not expected to cause any adverse effects, however, overuse of local anaesthetics can cause keratitis, with loss of corneal epithelium and stromal opacity.


Go to top of the page
5. PHARMACOLOGICAL PROPERTIES

Go to top of the page
5.1 Pharmacodynamic properties

Lidocaine is an established topical anaesthetic which blocks the sensory nerve endings of the cornea.

The fluorescein moiety does not stain a normal cornea but conjunctival abrasions are stained yellow or orange, corneal abrasions or ulcers are stained a bright green and foreign bodies are surrounded by a green ring.


Go to top of the page
5.2 Pharmacokinetic properties

None relevant.


Go to top of the page
5.3 Preclinical safety data

There are no preclinical data of relevance to the prescriber which are additional to that already included in other sections of the SPC.


Go to top of the page
6. PHARMACEUTICAL PARTICULARS

Go to top of the page
6.1 List of excipients

Povidone

Hydrochloric Acid

Purified Water


Go to top of the page
6.2 Incompatibilities

None known.


Go to top of the page
6.3 Shelf life

15 months.


Go to top of the page
6.4 Special precautions for storage

Store below 25°C. Do not freeze. Protect from light.


Go to top of the page
6.5 Nature and contents of container

A sealed, conical shaped container fitted with a twist and pull-off cap. Each Minims unit is overwrapped in an individual polypropylene/paper pouch. Each container holds approximately 0.5ml of solution.


Go to top of the page
6.6 Special precautions for disposal and other handling

Each Minims unit should be discarded after a single use.


Go to top of the page
7. MARKETING AUTHORISATION HOLDER

Chauvin Pharmaceuticals Ltd

106 London Road

Kingston-upon-Thames

Surrey

KT2 6TN


Go to top of the page
8. MARKETING AUTHORISATION NUMBER(S)

PL 0033/0073


Go to top of the page
9. DATE OF FIRST AUTHORISATION/RENEWAL OF THE AUTHORISATION

Date of first Authorisation: 14.6.78


Go to top of the page
10. DATE OF REVISION OF THE TEXT

June 2007



More information about this product

Link to this document from your website: http://www.medicines.org.uk/emc/medicine/16962/SPC/


Active Ingredients/Generics

 
   fluorescein sodium
   lidocaine hydrochloride